INDV Indivior Pharmaceuticals, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: specialty pharmaceuticals focused on addiction treatment and opioid dependence therapies
• • Emphasis on SUBLOCADE growth driving expected decline in U.S. revenue share from international markets this year
• • Increasing regulatory focus on data privacy and security with rising investments and risks related to AI integration and cyber threats
• • Foreign exchange risk heightened by 85% U.S. revenue concentration in 2025 and limited active currency hedging strategy
• • Noteworthy: AI-related risks and vendor use of generative AI highlighted as emerging compliance and security challenges

Risk Factors

• • FDA-required 2022 label change on SUBOXONE Film due to dental injury risk triggering ongoing product liability lawsuits
• • Exposure to U.K. Financial Services and Markets Act 2000 claims over alleged misleading disclosure about SUBOXONE product-hopping scheme
• • Single or dual sourcing for most raw materials and APIs risks supply interruption with average 36-month technology transfer delay to new suppliers
• • 2023 entry of a competitor’s extended-release injectable buprenorphine challenges SUBLOCADE’s market share in once-monthly OUD treatment
• • Leveraged balance sheet and term loan covenants constraining financial flexibility amid potential revenue declines

Management Discussion & Analysis

• • Revenue increased by $87M in 2025 vs $28M in 2024 from prior year performance obligations adjustments
• • No profitability or operating margin figures disclosed in the text
• • No segment performance data provided
• • No cash flow, capital allocation, buybacks, dividends, or capex details included
• • No forward-looking guidance or risk outlook mentioned in the provided section

What are the latest INDV SEC filings in 2026?

Indivior Pharmaceuticals, Inc. (INDV) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did INDV file its most recent 10-K annual report?

Indivior Pharmaceuticals, Inc. (INDV) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view INDV 10-Q quarterly reports?

Indivior Pharmaceuticals, Inc. (INDV)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every INDV 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has INDV filed recently?

Indivior Pharmaceuticals, Inc. (INDV)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find INDV insider trading activity (Form 4)?

SignalX aggregates every INDV Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does INDV file with the SEC?

Indivior Pharmaceuticals, Inc. (INDV) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new INDV filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Indivior Pharmaceuticals, Inc. (INDV).

What is INDV's SEC CIK number?

Indivior Pharmaceuticals, Inc. (INDV)'s SEC CIK (Central Index Key) number is 1625297. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1625297 to look up all INDV filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find INDV return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Indivior Pharmaceuticals, Inc. (INDV) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.